Sign in
Not yet taking people in United StatesPhase 4

Suzetrigine for pain control after knee replacement surgery for knee arthritis

Tests suzetrigine added to pain care in adults having knee replacement.

Key facts

Who runs it
Emory University
Where
Atlanta, United StatesSee the 3 sites
Trial code
Registry title
Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty
Status
Not yet recruiting
Phase
Phase 4
People taking part
75 people, planned
Started
Jul 2026
Expected to end
Aug 2028
Type of study
Interventional
Treatments tested
  • Suzetrigine
Record updated
3 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults having a first total knee replacement for knee osteoarthritis. Everyone gets Suzetrigine with other pain medicines around surgery.

Age
18 to 95 years
Sex
All sexes
Disease stage
Knee osteoarthritis needing a first (primary) total knee replacement.
Earlier treatment
People cannot join if they used opioid pain medicines daily less than 4 weeks before surgery. People who take glucocorticoids every day cannot join.
Biomarker or test result
People with diabetes, defined as an A1C greater than 6.5% (48 mmol/mol), cannot join.

Main reasons for not taking part

  • Severe heart disease (NYHA2), kidney failure or liver problems
  • Pregnancy
  • A weak immune system, local infections, or other serious injuries
  • Unable to take NSAIDs, or taking CYP3A inhibitors
  • Clot prevention other than Aspirin (81mg) twice daily

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Patients undergoing primary total knee arthroplasty for osteoarthritis of the knee
  • Patients between the ages of 18 and 95 years

Who cannot take part

  • Patients with concurrent and significant injuries to other bones or organs
  • Patients with preoperative opioid use, defined as daily use less than 4 weeks before the index surgery
  • Patients currently taking CYP3A inhibitors
  • Patients with local infections
  • Patients with a history of severe heart disease (NYHA2), renal failure, or liver dysfunction
  • Patients with active peptic ulcer disease
  • Patients neurological or psychiatric diseases, potentially influencing pain perception
  • Patients with a history of alcohol or medical abuse, allergies to glucocorticoids, current daily use of glucocorticoids
  • Patients who receive Deep Venous Thrombosis (DVT) prophylaxis different than Aspirin (81mg) twice daily (BID)
  • Patients who have known diabetes mellitus as defined with an A1C greater than 6.5%
  • Minors unable to provide informed consent for participation in the study
  • Subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures
  • Patients with pre-existing immune suppression, where further immune suppression with GCs could warrant unwarranted or unneeded risk
  • Patients who are pregnant
  • Patients who are unable to take NSAIDs

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 95 years old?

Where in United States

  • Emory ClinicAtlanta, United StatesContact: Darrell FavorsNot yet recruiting
  • Emory Clinic at Executive ParkAtlanta, United StatesContact: Darrell FavorsNot yet recruiting
  • Emory Orthopaedics and Spine CenterAtlanta, United StatesContact: Darrell FavorsNot yet recruiting

About the trial

What the trial wants to find out

This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in addition to standard of care.

The group in the trial

  • Suzetrigine Regimen ArmTreatment being tested

    Suzetrigine (JOURNAVX®) administered orally consisting of a course that lasts up to a maximum of 14 days. The starting dose will be 100 mg orally taken as two 50 mg tablets on an empty stomach (at least 1 hour before or 2 hours after food). Maintenance dosing will begin 12 hours after the initial dose, at which point patients will take 50 mg orally every 12 hours.

    Treatment: Suzetrigine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty
Plain-language title
Suzetrigine for pain control after knee replacement surgery for knee arthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07624526, who can take part
Record updated
3 June 2026